InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
68,129.01
(
0.32%
)
Post# of 12660
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

exwannabe

Send PM Follow Ignore
Followers 89
Posts 17559
Boards Moderated 0
Alias Born 09/06/2006

exwannabe

Re: newporter post# 5120

Monday, 11/26/2007 11:26:34 PM

Monday, November 26, 2007 11:26:34 PM

Post# of 12660
RE: That seems like a big advantage ...

IWFAL (one of the resident stat experts) stated that the tail doesn't help the p value a real lot because there are so few patients let in the comparison arm.

This makes sence for log-rank, because once the treatment patients live longer than the placebo patients it doesn't matter at all how much longer they go. Only the order of events matter.

But for COX this doesn't seam right to me.

Clark (if you'r out there), was your comment for log rank only, or not?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up